Skip to main content
. 2015 Jan 5;33(7):716–722. doi: 10.1200/JCO.2014.57.2743

Table 1.

Overview of Two RCTs of ADT With or Without RT

graphic file with name zlj00715-4958-t01.jpg

Characteristic NCIC CTG (Warde et al,4 2011) SPCG-7 (Widmark et al,3 2009)
Eligibility
    Age, years < 80 < 76
    Stage and WHO grade Clinical T2, grade 2/3 Clinical T1b-T2, grade 2/3
Clinical T3, grade 1-3 Clinical T3, grade 1-3
Primary end point All-cause mortality Cause-specific mortality
Sample size 1,205 875
Selected characteristics
    Median age, years 70 66
    Clinical stage T1, % 0 2
    Clinical stage T3, % 83 78
    WHO grade 3, %* 18 19
    PSA < 20 ng/mL, % 37 60

Abbreviations: ADT, androgen-deprivation therapy; NCIC CTG, National Cancer Institute of Canada Clinical Trials Group; PSA, prostate-specific antigen; RCT, randomized clinical trial; RT, radiotherapy; SPCG-7, Scandinavian Prostate Cancer Group Study 7.

*

WHO grade 3 is equivalent to Gleason score 8 to 10.